| Index | S&P 500 | P/E | 13.70 | EPS (ttm) | 6.07 | Insider Own | 0.15% | Shs Outstand | 413.22M | Perf Week | 2.73% |
| Market Cap | 34.37B | Forward P/E | 13.13 | EPS next Y | 6.34 | Insider Trans | 1.92% | Shs Float | 412.37M | Perf Month | 19.36% |
| Enterprise Value | 41.93B | PEG | 1.53 | EPS next Q | 1.51 | Short Float | 4.25% | Perf Quarter | 9.39% | ||
| Income | 2.62B | P/S | 3.61 | EPS this Y | -1.99% | Short Ratio | 3.33 | Perf Half Y | -26.18% | ||
| Sales | 9.52B | P/B | 10.92 | EPS next Y | 1.97% | ROA | 17.35% | Short Interest | 17.52M | Perf YTD | -33.89% |
| Book/sh | 7.62 | P/C | 20.51 | EPS next 5Y | 8.94% | ROE | 69.25% | 52W High | 144.83 -42.57% | Perf Year | -42.28% |
| Cash/sh | 4.06 | P/FCF | 14.53 | EPS past 3/5Y | 10.27% 11.97% | ROIC | 21.63% | 52W Low | 68.77 20.95% | Perf 3Y | -47.38% |
| Dividend Est. | 2.12 (2.55%) | EV/EBITDA | 10.50 | Sales past 3/5Y | 5.42% 7.24% | Gross Margin | 70.87% | Volatility | 2.60% 2.39% | Perf 5Y | -60.68% |
| Dividend TTM | 2.12 (2.55%) | EV/Sales | 4.41 | EPS Y/Y TTM | 4.48% | Oper. Margin | 37.00% | ATR (14) | 1.97 | Perf 10Y | 63.29% |
| Dividend Ex-Date | Oct 30, 2026 | Quick Ratio | 1.83 | Sales Y/Y TTM | 1.41% | Profit Margin | 27.49% | RSI (14) | 68.48 | Recom | 2.53 |
| Dividend Gr. 3/5Y | 15.44% 20.11% | Current Ratio | 3.08 | EPS Q/Q | 6.25% | SMA20 | 7.00% | Beta | 0.66 | Target Price | 84.75 |
| Payout | 33.98% | Debt/Eq | 2.93 | Sales Q/Q | 0.33% | SMA50 | 10.67% | Rel Volume | 1.09 | Prev Close | 79.72 |
| Employees | 14,500 | LT Debt/Eq | 2.93 | Earnings | Nov 05 | SMA200 | -10.86% | Avg Volume | 4.95M | Price | 83.18 |
| IPO Date | Feb 01, 2013 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 0.95% -1.34% | Net Debt/EBITDA | 1.89 | Volume | 5,410,674 | Change | 4.34% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-29-26 | Reiterated | Morgan Stanley | Overweight | $85 → $82 |
| Oct-20-26 | Downgrade | Jefferies | Buy → Hold | $254 → $83 |
| Oct-16-26 | Initiated | Goldman Sachs | Neutral | $74 |
| Aug-25-26 | Reiterated | Cantor Fitzgerald | $94 | |
| Aug-20-26 | Reiterated | Stifel Nicolaus | Buy | $85 → $80 |
| Aug-07-26 | Reiterated | Morgan Stanley | Overweight | $99 → $85 |
| Aug-06-26 | Downgrade | William Blair | Outperform → Market Perform | |
| Jul-27-26 | Reiterated | UBS | Neutral | $99 → $85 |
| Jul-22-26 | Reiterated | Morgan Stanley | Overweight | $115 → $99 |
| Jul-06-26 | Reiterated | HSBC | Buy | $140 → $95 |
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 9,517 | 9,467 | 9,256 | 8,544 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 2,772 | 2,794 | 2,860 | 2,710 | — | — | — | — | — | |
| Gross Profit | 6,745 | 6,673 | 6,396 | 5,834 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 2,378 | 2,378 | 2,318 | 2,151 | — | — | — | — | — | |
| Research and Development | 722 | 698 | 686 | 614 | — | — | — | — | — | |
| Other Operating Expense | 124 | 0 | 0 | 0 | — | — | — | — | — | |
| Operating Income | 3,521 | 3,597 | 3,392 | 3,069 | — | — | — | — | — | |
| Interest Expense | 244 | 243 | 242 | 258 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -5 | 6 | -17 | 125 | — | — | — | — | — | |
| Net Income Before Taxes | 3,272 | 3,360 | 3,133 | 2,936 | — | — | — | — | — | |
| Income Taxes | 656 | 687 | 637 | 596 | — | — | — | — | — | |
| Consolidated Net Income | 2,616 | 2,673 | 2,486 | 2,344 | — | — | — | — | — | |
| Net Income From Continuing Operations | 2,616 | 2,673 | 2,496 | 2,340 | — | — | — | — | — | |
| Net Income | 2,616 | 2,673 | 2,486 | 2,344 | — | — | — | — | — | |
| EPS (Recurring) | 6.08 | 6.03 | 5.47 | 5.08 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 6.08 | 6.03 | 5.47 | 5.08 | — | — | — | — | — | |
| EPS (Diluted) | 6.07 | 6.02 | 5.47 | 5.07 | — | — | — | — | — | |
| EBITDA | 3,993 | 4,069 | 3,872 | 3,685 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 13.70 | 20.90 | 29.79 | 38.93 | — | — | — | — | — | |
| Price To Sales Ratio | 3.65 | 5.89 | 7.99 | 10.65 | — | — | — | — | — | |
| Gross Margin | 70.87 | 70.49 | 69.10 | 68.28 | — | — | — | — | — | |
| Operating Margin | 37.00 | 38.00 | 36.65 | 35.92 | — | — | — | — | — | |
| Net Margin | 27.49 | 28.23 | 26.86 | 27.43 | — | — | — | — | — | |
| Shares Outstanding | 418 | 443 | 454 | 461 | — | — | — | — | — | |
| Market Capitalization | 34,769 | 55,738 | 73,970 | 90,988 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| FULLER JULIE | Executive Vice President | Sep 30 '26 | Option Exercise | 0.00 | 799 | 0 | 1,862 | Oct 02 |
| Stetter Mark | Director | May 21 '26 | Option Exercise | 0.00 | 1,572 | 0 | 1,572 | May 26 |
| PARENT LOUISE M | Director | May 20 '26 | Option Exercise | 0.00 | 22,317 | 0 | 28,394 | May 21 |
| Bisaro Paul | Director | May 13 '26 | Buy | 75.88 | 2,000 | 151,750 | 27,862 | May 13 |
| DAMELIO FRANK A | Director | May 13 '26 | Buy | 75.39 | 6,650 | 501,344 | 21,458 | May 13 |
| MCCALLISTER MICHAEL B | Director | May 11 '26 | Buy | 77.76 | 3,000 | 233,273 | 24,524 | May 12 |
| Esch Kevin | Executive Vice President | Apr 30 '26 | Option Exercise | 0.00 | 519 | 0 | 653 | May 01 |
| Sarbaugh Keith | Executive Vice President | Mar 31 '26 | Option Exercise | 0.00 | 1,528 | 0 | 3,870 | Apr 01 |
| MCCALLISTER MICHAEL B | Director | Feb 19 '26 | Option Exercise | 0.00 | 1,619 | 0 | 1,622 | Feb 23 |
| Norden Gregory | Director | Feb 19 '26 | Option Exercise | 0.00 | 1,619 | 0 | 1,619 | Feb 23 |
| Broadhurst Vanessa | Director | Feb 19 '26 | Option Exercise | 0.00 | 1,619 | 0 | 4,437 | Feb 23 |
| FULLER JULIE | Executive Vice President | Feb 19 '26 | Option Exercise | 0.00 | 750 | 0 | 1,353 | Feb 23 |
| Joseph Wetteny | Chief Financial Officer | Feb 19 '26 | Option Exercise | 0.00 | 4,101 | 0 | 22,816 | Feb 23 |
| PECK KRISTIN C | Chief Executive Officer | Feb 19 '26 | Option Exercise | 0.00 | 14,709 | 0 | 108,691 | Feb 23 |
| Ashton Nicholas | Executive Vice President | Feb 19 '26 | Option Exercise | 0.00 | 750 | 0 | 2,214 | Feb 23 |